Table 2 Unique mutated genes in each treatment group
Mutated genes | IC and ST (30 samples) | IC without ST (11 samples) | ST without IC (12 samples) | Neither IC nor ST (9 samples) |
|---|---|---|---|---|
ERBB3 | 5.26% | WT | WT | WT |
FGFR3 | 5.26% | WT | WT | WT |
FGFR4 | 5.26% | WT | WT | WT |
GAS6 | 5.26% | WT | WT | WT |
GNA11 | 5.26% | WT | WT | WT |
KNSTRN | 5.26% | WT | WT | WT |
MED12 | 5.26% | WT | WT | WT |
MTOR | 5.26% | WT | WT | WT |
MYCN | 5.26% | WT | WT | WT |
NFE2L2 | 5.26% | WT | WT | WT |
TIAF1 | 5.26% | WT | WT | WT |
AKT1 | 10.53% | WT | WT | WT |
FBXW7 | 10.53% | WT | WT | WT |
HRAS | 10.53% | WT | WT | WT |
ABL1 | 15.79% | WT | WT | WT |
BAP1 | WT | 12.50% | WT | WT |
MAPK1 | WT | 12.50% | WT | WT |
SF3B1 | WT | 12.50% | WT | WT |
PIK3R1 | WT | 25.00% | WT | WT |
CSNK2A1 | WT | WT | 10.00% | WT |
IL6 | WT | WT | 10.00% | WT |
MET | WT | WT | 10.00% | WT |
SMAD4 | WT | WT | 10.00% | WT |
APEX1 | WT | WT | WT | 11.11% |
BCL9 | WT | WT | WT | 11.11% |